A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer-Reference-Cited by-同舟云学术

A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer

Published:2021-09-19 Issue: Volume: Page:
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Furrer Marc A.¹²³^ORCID,Papa Nathan⁴,Luetolf Sandro¹,Roth Beat¹⁵^ORCID,Cumberbatch Marcus⁶,Dorin Vartolomei Mihai⁷⁸,Thomas Benjamin C.²³^ORCID,Thoeny Harriet C.¹⁹,Seiler Roland¹,Thalmann George N.¹^ORCID,Kiss Bernhard¹^ORCID

Affiliation:

1. Department of Urology University Hospital of Bern University of Bern Bern Switzerland

2. Department of Urology The University of Melbourne Royal Melbourne Hospital Melbourne Vic. Australia

3. The Australian Medical Robotics Academy Melbourne Vic. Australia

4. School of Public Health and Preventive Medicine Monash University Melbourne Vic. Australia

5. Department of Urology University Hospital of Lausanne (CHUV) University of Lausanne Lausanne Switzerland

6. Department of Academic Urology University of Sheffield Sheffield UK

7. Department of Urology Comprehensive Cancer Centre Vienna General Hospital Medical University of Vienna Vienna Austria

8. Department of Cell and Molecular Biology Pharmacy, Sciences and Technology University of Medicine Targu‐Mures Romania

9. Department of Diagnostic and Interventional Radiology Hôpital Cantonal Fribourgois (HFR) University of Fribourg Fribourg Switzerland

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15579

Reference19 articles.

1. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

2. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data

3. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

4. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

5. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A more comprehensive assessment of pre-, intra-, and postoperative patient- and surgery-specific parameters and prehabilitation is required to improve pre-, peri- and postoperative risk estimation to optimize patient management with reduction of morbidity after major urological surgery;Urologic Oncology: Seminars and Original Investigations;2023-10

2. Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005;European Urology Focus;2023-10

3. Detailed reporting of clinical and pathological parameters, and comprehensive depiction of complication–intervention events and grading is required to ensure comparability of survival and morbidity outcomes;World Journal of Urology;2023-09-16

4. Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1;Urologic Oncology: Seminars and Original Investigations;2023-07